Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.69 (
BMT
)
2,655
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We asked in a retrospective analysis whether patients with diabetes mellitus or impaired glucose tolerance are at increased risk for morbidity and mortality after high-dose therapy followed by an autologous bone marrow transplantation. Nine patients with diabetes mellitus (n = 7) or impaired glucose tolerance (n = 2) were identified who had been treated with high-dose therapy and autologous bone marrow transplant for lymphoid malignancies. At the start of the pretransplant conditioning all patients had a Karnofsky score of at least 80 and no clinically demonstrable organ dysfunction. One patient with diabetes mellitus type I (DM I) was transplanted without any complications. The patients with diabetes mellitus type II (DM II) or an impaired glucose tolerance had complications of life-threatening infections (in 6/8), acute
renal insufficiency
(in 3/8), liver abnormalities with elevated liver enzymes or liver failure (in 4/8) and congestive heart failure (in 1/8). Although the complications observed are not infrequent in the transplant setting, because of the good performance status before
BMT
and the absence of clinically demonstrable organ impairment before transplantation, it is our impression that the presence of diabetes mellitus or glucose intolerance might be an important co-factor in the morbidity of these patients.
...
PMID:Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation. 229 95
Thirty seven patients with arterial hypertension of renal genesis (chronic diffuse glomerulonephritis, chronic pyelonephritis, renal cystic disease and congenital abnormalities) were subjected to NMR-tomography. The comparison group comprised 12 patients with essential hypertension and 18 normal individuals constituted the control group. The examination was effected in the axial, frontal and sagittal planes using the
BMT
-1100 NMR-tomograph (Brucker, FRG) with the magnetic intensity of 0.235 T, the coil diameter of 60 cm, and the working frequency of 9.95 MHz. The technique made it possible to draw conclusions as to the presence or absence of the kidneys, their form, size, location and the structure of their cortex and medulla. The anatomo-tomographic picture of the kidneys in patients with chronic diffuse glomerulonephritis without
renal insufficiency
resembled that in cases of essential hypertension. In patients with chronic pyelonephritis the kidney contour was uneven and when
renal insufficiency
was present the kidneys were small and the borderline the cortex and the medulla was poorly differentiated. The technique proved especially informative in renal cystic disease and congenital abnormalities (renal aplasia and hypoplasia). The results obtained were compared with the data provided by other examination techniques.
...
PMID:[Diagnostic potentials of NMR tomography of the kidneys of patients with symptomatic renal hypertension]. 406 86
Pentoxifylline (PTX) has recently been shown to modulate TNF-alpha production and to reduce the incidence and severity of all major complications after
BMT
, including mucositis, veno-occlusive disease,
renal insufficiency
, hypertension, and graft-versus-host disease. To analyze in detail the effect of PTX on immune complications after
BMT
, we investigated the immunomodulatory effect of PTX on immune responses in vitro. The continuous presence of PTX significantly reduced the proliferative response of PBMC to PHA stimulation and to alloantigens in a dose-dependent manner. Starting at concentrations of 100 micrograms/ml, PTX was able to inhibit and, at 1000 micrograms/ml, completely block mitogen-induced proliferation. Maximal inhibition of more than 90% (91 +/- 4%) was also observed at PTX concentrations of 1000 micrograms/ml in the mixed lymphocyte culture (MLR) and by addition on day 0. However, lower but still significant suppression (13 +/- 7%) was achieved at concentrations of 10 micrograms/ml PTX. The inhibitory capacity of PTX was increased by mAbs against TNF-alpha (34 +/- 5% additional suppression at 100 micrograms/ml PTX) and not reversed by the addition of rTNF-alpha. The effect of PTX on the generation of CTLs in vitro was studied in the cell-mediated lymphotoxicity assay. PTX (100 micrograms/ml) significantly inhibited (P = 0.0178) the in vitro generation of CTLs when PTX was added to the culture on day 0. PTX also showed profound modulatory properties in the NK assay, with a reduction of 23 +/- 3% in specific lysis at 10 micrograms/ml PTX and maximal reductions of 88 +/- 3% at 1000 micrograms/ml PTX. Immunomodulatory properties of PTX were not only associated with blockage of TNF-alpha, as shown by decreased mRNA expression and TNF-alpha values in the culture supernatants, but also with an impaired production of other cytokines and secondary messages such as IFN-gamma and neopterin. PTX treatment, however, did not affect IFN-alpha or IL-1 beta production, and IL-6 release was even increased. PTX, therefore, has profound immunomodulatory properties in vitro, which are associated with selective inhibition of cytokine release and can be enhanced by the addition of mAbs against TNF-alpha, but not reversed by the addition of rTNF-alpha.
...
PMID:Immune response modulation by pentoxifylline in vitro. 833 42
Bone marrow transplant-associated thrombotic microangiopathy (BMT-TM), usually associated with thrombocytopenia, microangiopathic haemolytic anaemia (MAHA) and
renal insufficiency
, has been reported to occur approximately 5-6 months after
BMT
. We report a case of relapsed malignant lymphoma complicated by
BMT
-TM of hyperacute onset, which has never been described in the literature. Our patient, a 52-year-old male, developed MAHA with gross haematuria, thrombocytopenia, lactate dehydrogenase elevation and
renal insufficiency
2 days after autologous PBSC transplantation following high-dose chemotherapy. Supportive treatment, ie glucocorticoid, fresh frozen plasma and haemodiafiltration were given, and thereafter the
BMT
-TM gradually improved. In heavily pretreated patients, caution should be exercised for possible occurrence of the
BMT
-TM of hyperacute onset.
...
PMID:Thrombotic microangiopathy of hyperacute onset after autologous peripheral blood stem cell transplantation in malignant lymphoma. 967 61